G1 Therapeutics, Inc. (GTHX)
Company Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer.
The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer.
In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.
The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD.
for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses.
G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| Country | United States |
| Founded | 2008 |
| IPO Date | May 17, 2017 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 148 |
| CEO | Mark Velleca |
Contact Details
Address:
700 Park Offices Drive Research Triangle Park, North Carolina 27709 United States | |
| Phone | 919 213 9835 |
| Website | g1therapeutics.com |
Stock Details
| Ticker Symbol | GTHX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001560241 |
| CUSIP Number | 3621LQ109 |
| ISIN Number | US3621LQ1099 |
| Employer ID | 26-3648180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John E. Bailey Jr. | Chief Executive Officer, President and Director |
| Jennifer K. Moses CPA | Chief Financial Officer |
| Dr. Mark A. Velleca M.D., Ph.D. | Senior Advisor and Director |
| Dr. Rajesh K. Malik Ch.B., M.B., M.D. | Chief Medical Officer and Senior Vice President of Research & Development |
| Mark Avagliano | Chief Business Officer |
| Andrew Perry | Chief Commercial Officer |
| Terry L. Murdock | Chief Operating Officer |
| Alexander D. Smith M.S. | Vice President of Technical Operations |
| Dr. Jay C. Strum Ph.D. | Chief Scientific Officer |
| William C. Roberts | Vice President of Investor Relations and Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2022 | 8-K | Current report |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 4, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 4, 2022 | 8-K | Current report |
| May 4, 2022 | EFFECT | Notice of Effectiveness |